- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:06 | Pharming Group N.V.: Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) | 2 | GlobeNewswire (USA) | ||
| Do | H.C. Wainwright maintains Buy rating on Pharming Group stock | 4 | Investing.com | ||
| Do | NICE issues final guidance endorsing Pharming's APDS therapy | 2 | Pharmaceutical Business Review | ||
| Do | Pharming Group N.V.: Pharming Group to report first quarter 2025 financial results on May 8 | 223 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results... ► Artikel lesen | |
| Mi | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mi | Pharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDS | 251 | GlobeNewswire (Europe) | For media and investors only
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS
Recommended for adult and pediatric patients 12 years of age and older... ► Artikel lesen | |
| 03.04. | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Q4/24 results/pipeline expansion - Buy | 236 | dpa-AFX | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 03.04.2025 / 17:08 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer... ► Artikel lesen | |
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 03.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | 5 | SEC Filings | ||
| 03.04. | Pharming Group N.V.: Pharming Group announces the filing of its 2024 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 28.03. | Pharming Group N.V.: Pharming Group to participate in April investor conferences | 226 | GlobeNewswire (Europe) | Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen | |
| 20.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.03. | Pharming Group N.V.: Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation | 350 | GlobeNewswire (Europe) | Multi-center clinical trial includes sites located in the US, UK and EU
Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs)
CVID patients demonstrate... ► Artikel lesen | |
| 18.03. | NICE recommends Pharming's Joenja as first treatment for ultra-rare immune disease APDS | 4 | PMLiVE | ||
| 16.03. | Pharming Group NV zeigt Umsatzwachstum und stabilisiert Verluste | 10 | IT BOLTWISE | ||
| 14.03. | What Analysts Are Saying About Pharming Stock | 10 | Benzinga.com | ||
| 14.03. | Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth | 2 | Seeking Alpha | ||
| 13.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Pharming reports Q4 results | 3 | Seeking Alpha | ||
| 13.03. | Pharming Group Swings To Q4 Profit | 5 | RTTNews |
Seite:
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 7,064 | -1,64 % | Intellia Therapeutics shares up after Wolfe upgrade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,957 | -4,00 % | PacBio, Davos Alzheimers Collaborative Join For North African Dementia Registry Project | WASHINGTON (dpa-AFX) - The Davos Alzheimers Collaborative, a global initiative to prevent Alzheimers disease and improve brain health, announced that PacBio (PACB) will be a technology partner... ► Artikel lesen | |
| CENTOGENE | 0,102 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,341 | +0,11 % | ATAI Life Sciences Aktie: Bericht über jüngste Finanztrends | Das Biotechnologie-Unternehmen erforscht innovative Substanzen gegen Depressionen und entwickelt neuartige Behandlungsmethoden für psychische Erkrankungen. ATAI Life Sciences treibt die Entwicklung... ► Artikel lesen | |
| BIOMERIEUX | 113,50 | -1,05 % | BIOMERIEUX: WATCHFIRE by bioMérieux: a PCR test to detect viruses and bacteria in wastewater and respond to potential infectious disease outbreaks | ||
| CYCLACEL | 0,296 | -100,00 % | Cyclacel Pharmaceuticals declares $0.15 dividend | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,100 | -1,79 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| GENUS | 18,600 | 0,00 % | Genus - Notification of Major Holdings | ||
| ABIONYX PHARMA | 1,160 | +0,17 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| ANAPTYSBIO | 18,200 | +0,55 % | AnaptysBio, Inc.: Anaptys Announces Stock Repurchase Plan | SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that... ► Artikel lesen | |
| MEIRAGTX | 5,650 | +0,89 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| AKESO | 11,400 | -0,87 % | Akeso, Inc.: Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma | HONG KONG, April 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration... ► Artikel lesen | |
| MAAT PHARMA | 6,000 | +2,39 % | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,155 | -1,71 % | Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan | Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,82 % bei einem Aktienkurs von 7,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.
